Infectious Diseases News and Research

RSS

VSV-based vaccine yields promising results for rapid development of effective Ebola vaccine

A live vaccine based on the "Vesicular Stomatitis Virus" (VSV) has yielded highly promising results for the rapid development of an effective vaccine against the Ebola virus. This vaccine would only need to be injected once for long-lasting immunoprotection.

2 Apr 2015

Registration opens for inaugural Stanford Medicine X|ED conference

Registration opened today for the inaugural Stanford Medicine X|ED conference, which will explore the role of technology and networked intelligence in shaping the future of medical education.

2 Apr 2015

LA BioMed scientist awarded $80,000 to study effectiveness of pulmonary rehab in treating COPD

The ATS Foundation and Breathe California of Los Angeles have awarded $80,000 to Harry Rossiter, PhD, a lead researcher at the Los Angeles Biomedical Research Institute, to study the effectiveness of pulmonary rehabilitation in reducing chronic obstructive pulmonary disease (COPD) symptoms in an underserved population in Los Angeles.

2 Apr 2015

Purdue researchers identify new class of chemical insecticides to control mosquitoes

Purdue researchers have identified a new class of chemical insecticides that could provide a safer, more selective means of controlling mosquitoes that transmit key infectious diseases such as dengue, yellow fever and elephantiasis.

2 Apr 2015

Hospitals, health systems preparing to treat patients with Ebola face unexpected challenges

Hospitals and health systems preparing for and treating patients with Ebola Virus Disease (EVD) in the fall of 2015 faced unexpected challenges for ensuring safety of staff, patients and the community. The experiences are detailed in two studies published online in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

2 Apr 2015

Canada's VSV-EBOV Ebola vaccine proves safe, effective in Phase 1 clinical trial

The Honourable Rona Ambrose, Minister of Health, and Canada's Chief Public Health Officer, Dr. Gregory Taylor, today welcomed the news of promising trial outcomes of Canada's VSV-EBOV Ebola vaccine. The results of several studies and trials bring the world closer to ending this global outbreak through the provision of a commercially available vaccine.

2 Apr 2015

NIH approves $6.6 million in funding for Phase 2a adult eradication study of Argos' AGS-004

Argos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis technology platform, today announced that the NIH Division of AIDS (DAIDS) has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company’s investigational fully personalized immunotherapy for HIV.

2 Apr 2015

NIH awards $2.1 million grant to counter antibiotic resistance in Gram-negative bacteria

The National Institutes of Health has awarded Dr. Walter Fast, associate professor of medicinal chemistry at The University of Texas at Austin's College of Pharmacy, a four-year $2.1 million grant to develop small-molecules that counter antibiotic resistance in Gram-negative bacteria. If successful, the research could lead to new drugs for treating bacterial infections that are resistant to most antibiotics.

1 Apr 2015

Roche launches new protein melting application for real-time PCR LightCycler 1536 instrument

Roche announced today the introduction of a new protein melting application for its high-throughput, real-time PCR LightCycler 1536 instrument. The fully automated platform now allows life science researchers to perform thermal shift assays (TSAs) in 1536-well applications quickly and consistently.

From Roche Sequencing and Life Science 31 Mar 2015

New research reveals how a deadly fungus grows and kills immune cells

New research from the University of Toronto has scientists re-thinking how a lethal fungus grows and kills immune cells. The study hints at a new approach to therapy for Candida albicans, one of the most common causes of bloodstream infections.

31 Mar 2015

New HCV therapies cost-effective in specific groups of HCV-infected patients

A study led by Boston Medical Center researchers demonstrates that while new therapies to treat Hepatitis C Virus (HCV) are highly effective, they are cost-effective and provide the greatest value in specific groups of HCV-infected patients.

31 Mar 2015

Compact MRI and multimodality: an interview with Bernard Siow, UCL

CABI is a preclinical imaging laboratory where we have about ten modalities. We started off with MRI and we have a 9.4T high-field system.

From Bruker BioSpin Group 30 Mar 2015

Study provides insights into climate, social factors that trigger dengue outbreaks

Researchers at Upstate Medical University, in collaboration with a team of international investigators studying dengue fever, have discovered new information on climate drivers of the disease and social risk factors that may be contributing to its spread, according to two scientific papers recently published in BMC Infectious Disease and BMC Public Health, open access, peer-reviewed online journals.

30 Mar 2015

Study finds link between neurodegenerative disorders and inflammation

Researchers from McMaster University and the Icahn School of Medicine at Mount Sinai, New York have discovered that a protein associated with neurodegenerative diseases like ALS also plays an important role in the body's natural antiviral response.

30 Mar 2015

Effective therapy enables immune system recovery in majority of children

Most children with HIV who have low levels of a key immune cell eventually recover levels of this cell after they begin treatment, according to a new study conducted by researchers at UCLA and other institutions in the U.S. and Brazil.

30 Mar 2015

Naldemedine meets primary and secondary endpoints in phase III study for OIC treatment

Naldemedine, an investigational peripherally acting mu-opioid receptor antagonist (PAMORA) under development by Shionogi & Co., Ltd., met its primary and secondary endpoints in a phase III study (COMPOSE I) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain receiving opioid therapy.

30 Mar 2015

Rare genetic mutation explains why flu can kill in rare cases

Nobody likes getting the flu, but for some people, fluids and rest aren't enough. A small number of children who catch the influenza virus fall so ill they end up in the hospital — perhaps needing ventilators to breathe — even while their family and friends recover easily. New research by Rockefeller University scientists, published March 26 in Science, helps explain why: a rare genetic mutation.

30 Mar 2015

Experimental nanoparticle therapy speeds healing of all sorts of wounds

An experimental therapy developed by researchers at Albert Einstein College of Medicine of Yeshiva University cut in half the time it takes to heal wounds compared to no treatment at all. Details of the therapy, which was successfully tested in mice, were published online in the Journal of Investigative Dermatology.

30 Mar 2015

Study suggests new approach to help prevent meningococcal outbreaks

Nasal drops of harmless bacteria can inhibit a related bug that sometimes causes meningococcal disease, according to new findings published online in Clinical Infectious Diseases. The study--conducted among college students, a group at higher risk for this often serious illness--suggests a new approach that could help suppress outbreaks of the disease, if supported by future research.

30 Mar 2015

Research: Common bacteria poised to become antibiotic-resistant superbugs

Antibiotic resistance is poised to spread globally among bacteria frequently implicated in respiratory and urinary infections in hospital settings, according to new research at Washington University School of Medicine in St. Louis.

30 Mar 2015

Infectious Diseases News and Research

VSV-based vaccine yields promising results for rapid development of effective Ebola vaccine

Registration opens for inaugural Stanford Medicine X|ED conference

LA BioMed scientist awarded $80,000 to study effectiveness of pulmonary rehab in treating COPD

Purdue researchers identify new class of chemical insecticides to control mosquitoes

Hospitals, health systems preparing to treat patients with Ebola face unexpected challenges

Canada's VSV-EBOV Ebola vaccine proves safe, effective in Phase 1 clinical trial

NIH approves $6.6 million in funding for Phase 2a adult eradication study of Argos' AGS-004

NIH awards $2.1 million grant to counter antibiotic resistance in Gram-negative bacteria

Roche launches new protein melting application for real-time PCR LightCycler 1536 instrument

New research reveals how a deadly fungus grows and kills immune cells

New HCV therapies cost-effective in specific groups of HCV-infected patients

Compact MRI and multimodality: an interview with Bernard Siow, UCL

Study provides insights into climate, social factors that trigger dengue outbreaks

Study finds link between neurodegenerative disorders and inflammation

Effective therapy enables immune system recovery in majority of children

Naldemedine meets primary and secondary endpoints in phase III study for OIC treatment

Rare genetic mutation explains why flu can kill in rare cases

Experimental nanoparticle therapy speeds healing of all sorts of wounds

Study suggests new approach to help prevent meningococcal outbreaks

Research: Common bacteria poised to become antibiotic-resistant superbugs

Industry Focus: Infectious Diseases eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News